Janssen/Arrowhead Deal History & Licensing Activity
Janssen/Arrowhead is a large pharma headquartered in US. Over the past three years, Janssen/Arrowhead has been involved in 10 licensing and acquisition transactions, with a primary focus on Oligonucleotides (10 deals).
Deals (12mo)
3
Active Trials
0
Top Modality
Oligonucleotides
Focus Area
Infectious Disease
Janssen/Arrowhead Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Janssen/Arrowhead in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| RNA programs (neurology, pulmonary, musculoskeletal) | Sarepta Therapeutics | Oligonucleotides | Unknown | collaboration | Jul 3, 2026 |
| JNJ-3989 | Arrowhead | Oligonucleotides | Unknown | license | Apr 1, 2026 |
| next-generation CAR-T therapies | Janssen | CAR-T | Unknown | collaboration | Mar 21, 2026 |
| LCAR-B38M | Janssen | CAR-T | Unknown | collaboration | Mar 21, 2026 |
| ARO-SNCA and additional CNS/neuromuscular siRNA programs | Novartis | Oligonucleotides | Preclinical | license | Oct 21, 2025 |
Janssen/Arrowhead Pipeline Focus
Therapeutic areas and modalities where Janssen/Arrowhead is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Janssen/Arrowhead Strategic Signals
Key indicators of Janssen/Arrowhead's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Janssen/Arrowhead's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Janssen/Arrowhead Licensing & Deal Activity
Janssen/Arrowhead is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, Janssen/Arrowhead ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Janssen/Arrowhead include Infectious Disease (4 deals and trials), Hematology (4 deals and trials), Neurology (4 deals and trials), and Option Deals (3 deals and trials). In terms of modality, Janssen/Arrowhead has shown particular interest in oligonucleotides, car-t, rnai.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Janssen/Arrowhead and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Janssen/Arrowhead's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.